Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 1
2007 2
2009 1
2010 1
2011 1
2012 1
2013 1
2015 3
2016 1
2017 2
2018 2
2019 2
2021 2
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer.
Chan AM, Aguirre B, Liu L, Mah V, Balko JM, Tsui J, Wadehra NP, Moatamed NA, Khoshchehreh M, Dillard CM, Kiyohara M, Elshimali Y, Chang HR, Marquez-Garban D, Hamilton N, Pietras RJ, Gordon LK, Wadehra M. Chan AM, et al. Among authors: marquez garban d. Cancers (Basel). 2024 Apr 12;16(8):1481. doi: 10.3390/cancers16081481. Cancers (Basel). 2024. PMID: 38672563 Free PMC article.
Progesterone Receptor Signaling in the Breast Tumor Microenvironment.
Boonyaratanakornkit V, McGowan EM, Márquez-Garbán DC, Burton LP, Hamilton N, Pateetin P, Pietras RJ. Boonyaratanakornkit V, et al. Among authors: marquez garban dc. Adv Exp Med Biol. 2021;1329:443-474. doi: 10.1007/978-3-030-73119-9_21. Adv Exp Med Biol. 2021. PMID: 34664251
Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC.
Young PA, Márquez-Garbán DC, Noor ZS, Moatamed N, Elashoff D, Grogan T, Romero T, Sasano H, Saito R, Rausch R, Hamilton N, Dubinett SM, Garon EB, Pietras RJ. Young PA, et al. Among authors: marquez garban dc. JTO Clin Res Rep. 2021 Feb 3;2(4):100150. doi: 10.1016/j.jtocrr.2021.100150. eCollection 2021 Apr. JTO Clin Res Rep. 2021. PMID: 34590007 Free PMC article.
Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ. Garon EB, et al. Among authors: marquez garban dc. Lung Cancer. 2018 Sep;123:91-98. doi: 10.1016/j.lungcan.2018.06.013. Epub 2018 Jun 22. Lung Cancer. 2018. PMID: 30089602 Free PMC article. Clinical Trial.
27 results